Prescribing information


Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Hear more from clinical professionals across the UK and their experiences with implementing and enrolling patients onto the You First programme. Our clinicians also discuss the benefits that the programme can have for both patients and the Trust.

You First: The benefits of a bespoke patient support programme

Listen to Nurse Manager Jenny Fleming, Associate Professor in Inflammatory Skin Diseases Miriam Wittmann and Hospital Pharmacist Anusha Patel discuss the benefits of You First as a bespoke patient support programme.

Implementing You First into clinical practice: Experience from Luton

Hear from Julie Begum, RCN Rheumatology Forum Chair and Specialist Lead Nurse, Luton & Dunstable NHS Trust as she discusses her experiences of using the You First programme in Luton and how the programme has supported her and her patients throughout the pandemic.


How to get You First set up in your Trust

In this video, Helen Rowan, You First NHS Account Manager, highlights the key processes involved in getting the You First programme set up in your Trust and how to get your patients enrolled onto the programme.


CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug.

Rate this content: 
No votes yet
UK | March 2022 | 173369

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]